Lantheus Holdings Inc. (LNTH)
LNTH trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$100.02
-0.09% on the day
Market cap
$6.5B
Mid cap
Revenue · 2025
$1.5B
+0.5% on 2024
Net income · 2025
$233.6M
15.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | LNTH on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001521036 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.5B |
| Net income | $233.6M |
| Operating income | $310.8M |
| Net margin | 15.2% |
| Operating margin | 20.2% |
| Revenue growth | +0.5% |
| Cash | $359.1M |
| Total assets | $2.2B |
| P/E (computed) | 28.0× |
| P/S (computed) | 4.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2020-05-14 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-14 |
| Latest proxy | DEFA14A | 2026-10-02 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.0% |
| 1 month | -0.6% |
| 3 months | -4.7% |
| Year to date | +50.5% |
| 1 year | +83.4% |
| From 52-week high | -9.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ORKA | Oruka Therapeutics Inc. | $78.19 | -2.69% | $5.2B |
| NEOG | Neogen Corporation | $11.73 | -2.25% | $2.6B |
| CLDX | Celldex Therapeutics Inc. | $28.25 | -4.01% | $2.2B |
| NTLA | Intellia Therapeutics Inc. | $11.91 | -5.33% | $1.7B |
| IDXX | IDEXX Laboratories Inc. | $520.31 | -0.69% | $41.0B |
| QDEL | QuidelOrtho Corporation | $14.10 | +6.42% | $966.9M |
| ACHV | Achieve Life Sciences Inc. Common Shares | $7.00 | -0.85% | $720.3M |
| NNNN | Anbio Biotechnology | $4.26 | -3.40% | $613.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier